NasdaqGS:MDGLBiotechs
Madrigal Weighs Pfizer MASH License And Insider Selling In Growth Plan
Madrigal Pharmaceuticals (NasdaqGS:MDGL) entered an exclusive global license agreement with Pfizer for the MASH candidate ervogastat.
The deal is intended to expand Madrigal's treatment pipeline focused on metabolic dysfunction associated steatohepatitis.
Around the same period, multiple insiders, including the CEO and board directors, recorded sales of Madrigal shares.
These transactions arrive alongside the licensing news, giving investors fresh information on both pipeline direction and...